In 2008, when physician leaders of large urology practices began to recognize the need for a formal association to help meet the challenges of the future, the Large Urology Group Practice Association (LUGPA) was established with the purpose of enhancing communication among large groups, allowing for benchmarking of operations, promoting quality clinical outcomes, developing new opportunities, and improving advocacy in the legislative and regulatory arenas.
Prostate Screenings Are a Cornerstone of Men’s Health
by Gary M. Kirsh, MD
Op-Ed originally published on TheHill.com, October 11, 2016
In recent weeks attuned readers have noticed significant research studies being shared about prostate cancer, which, unless addressed during patient-physician encounters, have the potential to leave men ill-informed about this common cancer. After skin cancer, prostate cancer is the second most common cancer among American men. According to the American Cancer Society there are more than 189,000 new prostate cancer cases each year; in fact, about one in seven men will be diagnosed with prostate cancer in their lifetimes.
Prostate cancer presents physicians and their patients with a quandary. On the one hand, prostate cancer is very prevalent, and most men do not die from it. On the other hand, in a subset of patients, prostate cancer is very aggressive, and it is actually the second leading cause of cancer deaths in men.
The variability in the behavior of prostate cancers is increasingly recognized by urologists, and technology is continuously evolving to allow urologists to establish customized care regimens for each patient. In some instances curative treatment such as surgery or radiation therapy is strongly advisable, while in many others watchful waiting and active monitoring is a much more appropriate approach. But, to make these decisions, patients and doctors must know if cancer is present in the first place.